Close Menu

NEW YORK (GenomeWeb) – Having just pulled down $8.5 million in funding from a $21.5 million Series B round closed in early 2012, Miragen Therapeutics is gearing up to file investigational new drug applications for up to two of its proprietary microRNA drug candidates before the end of this year.

In doing so, the company is laying the groundwork for clinical studies that it hopes will generate proof-of-concept data around its therapeutic approach in order to woo investors for a planned initial public offering next year, Miragen President and CEO Bill Marshall told GenomeWeb.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A man has confessed to the rape and murder of developmental biologist Suzanne Eaton, according to the New York Times.

The Irish Times reports that US lawmakers and law enforcement agencies are concerned about ties between the US and Chinese genomics firms.

Parents of children with spinal muscular atrophy tell the Washington Post they are pushing to get insurance coverage of Novartis's Zolgensma.

In PNAS this week: gene mutations in individuals with syndromic craniosynostosis, putative colorectal cancer drivers, and more.